Evidence map›Paper›PMID 39130760›Full record

ArticleGastro hep advances2023

Development of a Novel Ulcerative Colitis Endoscopic Mayo Score Prediction Model Using Machine Learning.

David T Rubin, Klaus Gottlieb, Jean-Frederic Colombel, Jean-Pierre Schott, Lavi Erisson, Bill Prucka, Sloane Allebes Phillips, John Kwon, Jonathan Ng, James McGill

Registry-linked trialAbstract read
In one paragraph

Article in Gastro hep advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02589665 (A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02589665 phase2completednot on this map

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis

TypeinterventionalSponsorEli Lilly and CompanyRan2015 to 2019Enrolled249ConditionsUlcerative ColitisArmsMirikizumab, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David T RubinUniversity of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology, Chicago, Illinois.
Klaus GottliebEli Lilly and Company, Immunology, Indianapolis, Indiana.
Jean-Frederic ColombelIcahn School of Medicine at Mount Sinai, Gastroenterology, New York, New York.
Jean-Pierre SchottIterative Scopes, Inc., Cambridge, Massachusetts.
Lavi ErissonIterative Scopes, Inc., Cambridge, Massachusetts.
Bill PruckaEli Lilly and Company, Advanced Analytics and Data Sciences, Indianapolis, Indiana.
Sloane Allebes PhillipsIterative Scopes, Inc., Cambridge, Massachusetts.
John KwonJanssen Pharmaceuticals, Immunology, Raritan, New Jersey.
Jonathan NgIterative Scopes, Inc., Cambridge, Massachusetts.
James McGillEli Lilly and Company, Immunology, Indianapolis, Indiana.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Endoscopic assessment is a co-primary end point in inflammatory bowel disease registration trials, yet it is subject to inter- and intraobserver variability. We present an original machine learning approach to Endoscopic Mayo Score (eMS) prediction in ulcerative colitis and report the model's performance in differentiating key levels of endoscopic disease activity on full-length procedure videos. Methods: Seven hundred ninety-three full-length videos with centrally-read eMS were obtained from 249 patients with ulcerative colitis, who participated in a phase II trial evaluating mirikizumab (NCT02589665). A video annotation approach was established to extract mucosal features and associated eMS classification labels from each video to be used as inputs for model training. The primary objective of the model was a categorical prediction of inactive vs active endoscopic disease evaluated against 2 independent test sets: a full set with a baseline single human expert read and a consensus subset in which 2 human reads agreed. Results: On the full test set of 147 videos, the model predicted inactive vs active endoscopic disease via the eMS with an area under the curve of 89%, accuracy of 84%, positive predictive value of 80%, and negative predictive value of 85%. In the consensus test set of 94 videos, the model predicted inactive vs active endoscopic disease with an area under the curve of 92%, accuracy of 89%, positive predictive value of 87%, and negative predictive value of 90%. Conclusion: We have demonstrated that this machine learning model supervised by mucosal features and eMS video annotations accurately differentiates key levels of endoscopic disease activity.

Indexed as

Artificial IntelligenceCentral ReadingDeep SupervisionInflammatory Bowel Disease

Identifiers

PMID39130760
PMCPMC11307476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.